As Biotechnology businesses, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and InflaRx N.V. (NASDAQ:IFRX), are affected by contrast. This especially applies to their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. N/A 0.00 127.50M -2.05 0.00
InflaRx N.V. N/A 0.00 N/A -1.42 0.00

Table 1 highlights Apellis Pharmaceuticals Inc. and InflaRx N.V.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 shows Apellis Pharmaceuticals Inc. and InflaRx N.V.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -48.3% -39.9%
InflaRx N.V. 0.00% -22.7% -21.9%


The Current Ratio of Apellis Pharmaceuticals Inc. is 14.9 while its Quick Ratio stands at 14.9. The Current Ratio of rival InflaRx N.V. is 18.7 and its Quick Ratio is has 18.7. InflaRx N.V. is better equipped to clear short and long-term obligations than Apellis Pharmaceuticals Inc.

Analyst Ratings

In next table is shown Apellis Pharmaceuticals Inc. and InflaRx N.V.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Apellis Pharmaceuticals Inc. 0 0 1 3.00
InflaRx N.V. 0 0 1 3.00

Apellis Pharmaceuticals Inc. has a 135.85% upside potential and an average price target of $45. On the other hand, InflaRx N.V.’s potential upside is 36.44% and its average price target is $58. Based on the results shown earlier, Apellis Pharmaceuticals Inc. is looking more favorable than InflaRx N.V., analysts view.

Insider and Institutional Ownership

Roughly 59.3% of Apellis Pharmaceuticals Inc. shares are owned by institutional investors while 58.4% of InflaRx N.V. are owned by institutional investors. 20.7% are Apellis Pharmaceuticals Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 23.33% 31.79% 16.7% -2.95% -0.43% 39.88%
InflaRx N.V. 16.4% 16.44% 25.22% 14.31% 39.39% 4.98%

For the past year Apellis Pharmaceuticals Inc. has stronger performance than InflaRx N.V.


On 5 of the 7 factors InflaRx N.V. beats Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *